LLY

1,070.33

+0.82%↑

JNJ

206.53

-1.07%↓

ABBV

229.06

+2.46%↑

UNH

327.58

-0.05%↓

AZN

91.41

+0.61%↑

LLY

1,070.33

+0.82%↑

JNJ

206.53

-1.07%↓

ABBV

229.06

+2.46%↑

UNH

327.58

-0.05%↓

AZN

91.41

+0.61%↑

LLY

1,070.33

+0.82%↑

JNJ

206.53

-1.07%↓

ABBV

229.06

+2.46%↑

UNH

327.58

-0.05%↓

AZN

91.41

+0.61%↑

LLY

1,070.33

+0.82%↑

JNJ

206.53

-1.07%↓

ABBV

229.06

+2.46%↑

UNH

327.58

-0.05%↓

AZN

91.41

+0.61%↑

LLY

1,070.33

+0.82%↑

JNJ

206.53

-1.07%↓

ABBV

229.06

+2.46%↑

UNH

327.58

-0.05%↓

AZN

91.41

+0.61%↑

Search

IQVIA Holdings Inc

Open

SectorHealthcare

222.04 0.28

Overview

Share price change

24h

Current

Min

220.25

Max

223.4

Key metrics

By Trading Economics

Income

66M

332M

Sales

83M

4.1B

P/E

Sector Avg

30.761

76.798

Profit margin

8.098

Employees

91,000

EBITDA

102M

883M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+10.58% upside

Market Stats

By TradingEconomics

Market Cap

596M

38B

Previous open

221.76

Previous close

222.04

News Sentiment

By Acuity

50%

50%

167 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

IQVIA Holdings Inc Chart

Past performance is not a reliable indicator of future results.

Related News

18 Dec 2025, 23:54 UTC

Hot Stocks

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 Dec 2025, 23:51 UTC

Earnings

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 Dec 2025, 23:39 UTC

Major Market Movers

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 Dec 2025, 22:57 UTC

Acquisitions, Mergers, Takeovers

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 Dec 2025, 21:40 UTC

Earnings

Nike Sales Tick Up, But China Weakness Persists

18 Dec 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 Dec 2025, 23:37 UTC

Market Talk
Earnings

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 Dec 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 Dec 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 Dec 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 Dec 2025, 23:00 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 Dec 2025, 22:59 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 Dec 2025, 22:58 UTC

Acquisitions, Mergers, Takeovers

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 Dec 2025, 22:57 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 Dec 2025, 22:56 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 Dec 2025, 22:55 UTC

Earnings

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 Dec 2025, 21:59 UTC

Earnings

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 Dec 2025, 21:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

18 Dec 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 Dec 2025, 21:35 UTC

Earnings

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 Dec 2025, 21:31 UTC

Earnings

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 Dec 2025, 21:15 UTC

Earnings

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 Dec 2025, 21:15 UTC

Earnings

Nike 2Q Greater China Rev Down 17% >NKE

18 Dec 2025, 21:15 UTC

Earnings

Nike 2Q EPS 53c >NKE

18 Dec 2025, 21:15 UTC

Earnings

Nike 2Q Apparel Rev $3.91B >NKE

18 Dec 2025, 21:15 UTC

Earnings

Nike 2Q Equipment Rev $550M >NKE

18 Dec 2025, 21:15 UTC

Earnings

Nike 2Q N Amer Rev $5.63B >NKE

18 Dec 2025, 21:15 UTC

Earnings

Nike 2Q Footwear Rev $7.66B >NKE

18 Dec 2025, 21:15 UTC

Earnings

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 Dec 2025, 21:15 UTC

Earnings

Nike 2Q Greater China Rev $1.42B >NKE

Peer Comparison

Price change

IQVIA Holdings Inc Forecast

Price Target

By TipRanks

10.58% upside

12 Months Forecast

Average 244.85 USD  10.58%

High 273 USD

Low 200 USD

Based on 15 Wall Street analysts offering 12 month price targets forIQVIA Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

12

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

150.68 / 153.45Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Neutral Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

167 / 374 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat